Cybin Inc. announced that the United States Patent and Trademark Office granted U.S. patent 12,318,477 in support of its CYB004 deuterated DMT program. This program is currently in Phase 2 development for the treatment of Generalized Anxiety Disorder (GAD).
The newly issued patent includes claims to novel formulations of N,N-dimethyltryptamine (DMT) and deuterated isotopologues for intramuscular (IM) injection, including CYB004. This patent is expected to provide exclusivity until 2040, reinforcing the program's long-term commercial potential.
Cybin's intellectual property portfolio now comprises more than 90 granted patents and over 230 pending applications, establishing one of the strongest IP positions in the sector. Dosing is currently underway in the Phase 2 study evaluating CYB004 in GAD, with completion expected around mid-year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.